GABA Receptor Agonist Drug Industry Research Report 2025
Description
Summary
According to APO Research, the global GABA Receptor Agonist Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for GABA Receptor Agonist Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for GABA Receptor Agonist Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for GABA Receptor Agonist Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of GABA Receptor Agonist Drug include Novartis, Eli Lilly and Company, Pfizer, GlaxoSmithKline, AstraZeneca, XenoPort, VIVUS, sanofi-aventis and OVATION Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GABA Receptor Agonist Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GABA Receptor Agonist Drug.
The report will help the GABA Receptor Agonist Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The GABA Receptor Agonist Drug market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global GABA Receptor Agonist Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
GABA Receptor Agonist Drug Segment by Company
Novartis Eli Lilly and Company Pfizer GlaxoSmithKline AstraZeneca XenoPort VIVUS sanofi-aventis OVATION Pharmaceuticals Osmotica Pharmaceutical NovaDel Pharma H.LundBeck, Merck and Co Elan Corporation Biocodex Athena Drug Delivery Solutions AdvicenneGABA Receptor Agonist Drug Segment by Type
Baclofen Bamaluzole Phenibut Gaboxadol Klonopin (clonazepam) TiagbineGABA Receptor Agonist Drug Segment by Application
Alzheimer Epilepsy and Seizure Obesity and Alcoholism Anxiety and Sleep Disorders Psychiatric Disorders and Depression Attention Deficit Hyperactivity Disorder (ADHD)GABA Receptor Agonist Drug Segment by Region
North America United States Canada Europe Germany France U.K. Italy Netherlands Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Colombia Middle East & Africa Turkey Saudi Arabia UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABA Receptor Agonist Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GABA Receptor Agonist Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABA Receptor Agonist Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of GABA Receptor Agonist Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of GABA Receptor Agonist Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of GABA Receptor Agonist Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global GABA Receptor Agonist Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for GABA Receptor Agonist Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for GABA Receptor Agonist Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for GABA Receptor Agonist Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of GABA Receptor Agonist Drug include Novartis, Eli Lilly and Company, Pfizer, GlaxoSmithKline, AstraZeneca, XenoPort, VIVUS, sanofi-aventis and OVATION Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GABA Receptor Agonist Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GABA Receptor Agonist Drug.
The report will help the GABA Receptor Agonist Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The GABA Receptor Agonist Drug market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global GABA Receptor Agonist Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
GABA Receptor Agonist Drug Segment by Company
Novartis Eli Lilly and Company Pfizer GlaxoSmithKline AstraZeneca XenoPort VIVUS sanofi-aventis OVATION Pharmaceuticals Osmotica Pharmaceutical NovaDel Pharma H.LundBeck, Merck and Co Elan Corporation Biocodex Athena Drug Delivery Solutions AdvicenneGABA Receptor Agonist Drug Segment by Type
Baclofen Bamaluzole Phenibut Gaboxadol Klonopin (clonazepam) TiagbineGABA Receptor Agonist Drug Segment by Application
Alzheimer Epilepsy and Seizure Obesity and Alcoholism Anxiety and Sleep Disorders Psychiatric Disorders and Depression Attention Deficit Hyperactivity Disorder (ADHD)GABA Receptor Agonist Drug Segment by Region
North America United States Canada Europe Germany France U.K. Italy Netherlands Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Colombia Middle East & Africa Turkey Saudi Arabia UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABA Receptor Agonist Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GABA Receptor Agonist Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABA Receptor Agonist Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of GABA Receptor Agonist Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of GABA Receptor Agonist Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of GABA Receptor Agonist Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
134 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global GABA Receptor Agonist Drug Market Size (2020-2031)
- 2.2.2 Global GABA Receptor Agonist Drug Sales (2020-2031)
- 2.2.3 Global GABA Receptor Agonist Drug Market Average Price (2020-2031)
- 2.3 GABA Receptor Agonist Drug by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Baclofen
- 2.3.3 Bamaluzole
- 2.3.4 Phenibut
- 2.3.5 Gaboxadol
- 2.3.6 Klonopin (clonazepam)
- 2.3.7 Tiagbine
- 2.4 GABA Receptor Agonist Drug by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Alzheimer
- 2.4.3 Epilepsy and Seizure
- 2.4.4 Obesity and Alcoholism
- 2.4.5 Anxiety and Sleep Disorders
- 2.4.6 Psychiatric Disorders and Depression
- 2.4.7 Attention Deficit Hyperactivity Disorder (ADHD)
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global GABA Receptor Agonist Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global GABA Receptor Agonist Drug Sales (k units) of Manufacturers (2020-2025)
- 3.3 Global GABA Receptor Agonist Drug Revenue of Manufacturers (2020-2025)
- 3.4 Global GABA Receptor Agonist Drug Average Price by Manufacturers (2020-2025)
- 3.5 Global GABA Receptor Agonist Drug Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of GABA Receptor Agonist Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of GABA Receptor Agonist Drug, Product Type & Application
- 3.8 Global Manufacturers of GABA Receptor Agonist Drug, Established Date
- 3.9 Global GABA Receptor Agonist Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Novartis GABA Receptor Agonist Drug Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Eli Lilly and Company
- 4.2.1 Eli Lilly and Company Company Information
- 4.2.2 Eli Lilly and Company Business Overview
- 4.2.3 Eli Lilly and Company GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Eli Lilly and Company GABA Receptor Agonist Drug Product Portfolio
- 4.2.5 Eli Lilly and Company Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Pfizer GABA Receptor Agonist Drug Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 GlaxoSmithKline
- 4.4.1 GlaxoSmithKline Company Information
- 4.4.2 GlaxoSmithKline Business Overview
- 4.4.3 GlaxoSmithKline GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 GlaxoSmithKline GABA Receptor Agonist Drug Product Portfolio
- 4.4.5 GlaxoSmithKline Recent Developments
- 4.5 AstraZeneca
- 4.5.1 AstraZeneca Company Information
- 4.5.2 AstraZeneca Business Overview
- 4.5.3 AstraZeneca GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 AstraZeneca GABA Receptor Agonist Drug Product Portfolio
- 4.5.5 AstraZeneca Recent Developments
- 4.6 XenoPort
- 4.6.1 XenoPort Company Information
- 4.6.2 XenoPort Business Overview
- 4.6.3 XenoPort GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 XenoPort GABA Receptor Agonist Drug Product Portfolio
- 4.6.5 XenoPort Recent Developments
- 4.7 VIVUS
- 4.7.1 VIVUS Company Information
- 4.7.2 VIVUS Business Overview
- 4.7.3 VIVUS GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 VIVUS GABA Receptor Agonist Drug Product Portfolio
- 4.7.5 VIVUS Recent Developments
- 4.8 sanofi-aventis
- 4.8.1 sanofi-aventis Company Information
- 4.8.2 sanofi-aventis Business Overview
- 4.8.3 sanofi-aventis GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 sanofi-aventis GABA Receptor Agonist Drug Product Portfolio
- 4.8.5 sanofi-aventis Recent Developments
- 4.9 OVATION Pharmaceuticals
- 4.9.1 OVATION Pharmaceuticals Company Information
- 4.9.2 OVATION Pharmaceuticals Business Overview
- 4.9.3 OVATION Pharmaceuticals GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 OVATION Pharmaceuticals GABA Receptor Agonist Drug Product Portfolio
- 4.9.5 OVATION Pharmaceuticals Recent Developments
- 4.10 Osmotica Pharmaceutical
- 4.10.1 Osmotica Pharmaceutical Company Information
- 4.10.2 Osmotica Pharmaceutical Business Overview
- 4.10.3 Osmotica Pharmaceutical GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Osmotica Pharmaceutical GABA Receptor Agonist Drug Product Portfolio
- 4.10.5 Osmotica Pharmaceutical Recent Developments
- 4.11 NovaDel Pharma
- 4.11.1 NovaDel Pharma Company Information
- 4.11.2 NovaDel Pharma Business Overview
- 4.11.3 NovaDel Pharma GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 NovaDel Pharma GABA Receptor Agonist Drug Product Portfolio
- 4.11.5 NovaDel Pharma Recent Developments
- 4.12 H.LundBeck, Merck and Co
- 4.12.1 H.LundBeck, Merck and Co Company Information
- 4.12.2 H.LundBeck, Merck and Co Business Overview
- 4.12.3 H.LundBeck, Merck and Co GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 H.LundBeck, Merck and Co GABA Receptor Agonist Drug Product Portfolio
- 4.12.5 H.LundBeck, Merck and Co Recent Developments
- 4.13 Elan Corporation
- 4.13.1 Elan Corporation Company Information
- 4.13.2 Elan Corporation Business Overview
- 4.13.3 Elan Corporation GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 Elan Corporation GABA Receptor Agonist Drug Product Portfolio
- 4.13.5 Elan Corporation Recent Developments
- 4.14 Biocodex
- 4.14.1 Biocodex Company Information
- 4.14.2 Biocodex Business Overview
- 4.14.3 Biocodex GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.14.4 Biocodex GABA Receptor Agonist Drug Product Portfolio
- 4.14.5 Biocodex Recent Developments
- 4.15 Athena Drug Delivery Solutions
- 4.15.1 Athena Drug Delivery Solutions Company Information
- 4.15.2 Athena Drug Delivery Solutions Business Overview
- 4.15.3 Athena Drug Delivery Solutions GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.15.4 Athena Drug Delivery Solutions GABA Receptor Agonist Drug Product Portfolio
- 4.15.5 Athena Drug Delivery Solutions Recent Developments
- 4.16 Advicenne
- 4.16.1 Advicenne Company Information
- 4.16.2 Advicenne Business Overview
- 4.16.3 Advicenne GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.16.4 Advicenne GABA Receptor Agonist Drug Product Portfolio
- 4.16.5 Advicenne Recent Developments
- 5 Global GABA Receptor Agonist Drug Market Scenario by Region
- 5.1 Global GABA Receptor Agonist Drug Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global GABA Receptor Agonist Drug Sales by Region: 2020-2031
- 5.2.1 Global GABA Receptor Agonist Drug Sales by Region: 2020-2025
- 5.2.2 Global GABA Receptor Agonist Drug Sales by Region: 2026-2031
- 5.3 Global GABA Receptor Agonist Drug Revenue by Region: 2020-2031
- 5.3.1 Global GABA Receptor Agonist Drug Revenue by Region: 2020-2025
- 5.3.2 Global GABA Receptor Agonist Drug Revenue by Region: 2026-2031
- 5.4 North America GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.4.1 North America GABA Receptor Agonist Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America GABA Receptor Agonist Drug Sales by Country (2020-2031)
- 5.4.3 North America GABA Receptor Agonist Drug Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.5.1 Europe GABA Receptor Agonist Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe GABA Receptor Agonist Drug Sales by Country (2020-2031)
- 5.5.3 Europe GABA Receptor Agonist Drug Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific GABA Receptor Agonist Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific GABA Receptor Agonist Drug Sales by Country (2020-2031)
- 5.6.3 Asia Pacific GABA Receptor Agonist Drug Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.7.1 South America GABA Receptor Agonist Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America GABA Receptor Agonist Drug Sales by Country (2020-2031)
- 5.7.3 South America GABA Receptor Agonist Drug Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa GABA Receptor Agonist Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa GABA Receptor Agonist Drug Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa GABA Receptor Agonist Drug Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global GABA Receptor Agonist Drug Sales by Type (2020-2031)
- 6.1.1 Global GABA Receptor Agonist Drug Sales by Type (2020-2031) & (k units)
- 6.1.2 Global GABA Receptor Agonist Drug Sales Market Share by Type (2020-2031)
- 6.2 Global GABA Receptor Agonist Drug Revenue by Type (2020-2031)
- 6.2.1 Global GABA Receptor Agonist Drug Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global GABA Receptor Agonist Drug Revenue Market Share by Type (2020-2031)
- 6.3 Global GABA Receptor Agonist Drug Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global GABA Receptor Agonist Drug Sales by Application (2020-2031)
- 7.1.1 Global GABA Receptor Agonist Drug Sales by Application (2020-2031) & (k units)
- 7.1.2 Global GABA Receptor Agonist Drug Sales Market Share by Application (2020-2031)
- 7.2 Global GABA Receptor Agonist Drug Revenue by Application (2020-2031)
- 7.2.1 Global GABA Receptor Agonist Drug Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global GABA Receptor Agonist Drug Revenue Market Share by Application (2020-2031)
- 7.3 Global GABA Receptor Agonist Drug Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 GABA Receptor Agonist Drug Value Chain Analysis
- 8.1.1 GABA Receptor Agonist Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 GABA Receptor Agonist Drug Production Mode & Process
- 8.2 GABA Receptor Agonist Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 GABA Receptor Agonist Drug Distributors
- 8.2.3 GABA Receptor Agonist Drug Customers
- 9 Global GABA Receptor Agonist Drug Analyzing Market Dynamics
- 9.1 GABA Receptor Agonist Drug Industry Trends
- 9.2 GABA Receptor Agonist Drug Industry Drivers
- 9.3 GABA Receptor Agonist Drug Industry Opportunities and Challenges
- 9.4 GABA Receptor Agonist Drug Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global GABA Receptor Agonist Drug Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global GABA Receptor Agonist Drug Sales (k units) of Manufacturers (2020-2025)
- Table 7. Global GABA Receptor Agonist Drug Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global GABA Receptor Agonist Drug Revenue of Manufacturers (2020-2025)
- Table 9. Global GABA Receptor Agonist Drug Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market GABA Receptor Agonist Drug Average Price (US$/unit) of Manufacturers (2020-2025)
- Table 11. Global GABA Receptor Agonist Drug Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of GABA Receptor Agonist Drug, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of GABA Receptor Agonist Drug, Product Type & Application
- Table 14. Global GABA Receptor Agonist Drug Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global GABA Receptor Agonist Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Novartis Company Information
- Table 19. Novartis Business Overview
- Table 20. Novartis GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 21. Novartis GABA Receptor Agonist Drug Product Portfolio
- Table 22. Novartis Recent Developments
- Table 23. Eli Lilly and Company Company Information
- Table 24. Eli Lilly and Company Business Overview
- Table 25. Eli Lilly and Company GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 26. Eli Lilly and Company GABA Receptor Agonist Drug Product Portfolio
- Table 27. Eli Lilly and Company Recent Developments
- Table 28. Pfizer Company Information
- Table 29. Pfizer Business Overview
- Table 30. Pfizer GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 31. Pfizer GABA Receptor Agonist Drug Product Portfolio
- Table 32. Pfizer Recent Developments
- Table 33. GlaxoSmithKline Company Information
- Table 34. GlaxoSmithKline Business Overview
- Table 35. GlaxoSmithKline GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 36. GlaxoSmithKline GABA Receptor Agonist Drug Product Portfolio
- Table 37. GlaxoSmithKline Recent Developments
- Table 38. AstraZeneca Company Information
- Table 39. AstraZeneca Business Overview
- Table 40. AstraZeneca GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 41. AstraZeneca GABA Receptor Agonist Drug Product Portfolio
- Table 42. AstraZeneca Recent Developments
- Table 43. XenoPort Company Information
- Table 44. XenoPort Business Overview
- Table 45. XenoPort GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 46. XenoPort GABA Receptor Agonist Drug Product Portfolio
- Table 47. XenoPort Recent Developments
- Table 48. VIVUS Company Information
- Table 49. VIVUS Business Overview
- Table 50. VIVUS GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 51. VIVUS GABA Receptor Agonist Drug Product Portfolio
- Table 52. VIVUS Recent Developments
- Table 53. sanofi-aventis Company Information
- Table 54. sanofi-aventis Business Overview
- Table 55. sanofi-aventis GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 56. sanofi-aventis GABA Receptor Agonist Drug Product Portfolio
- Table 57. sanofi-aventis Recent Developments
- Table 58. OVATION Pharmaceuticals Company Information
- Table 59. OVATION Pharmaceuticals Business Overview
- Table 60. OVATION Pharmaceuticals GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 61. OVATION Pharmaceuticals GABA Receptor Agonist Drug Product Portfolio
- Table 62. OVATION Pharmaceuticals Recent Developments
- Table 63. Osmotica Pharmaceutical Company Information
- Table 64. Osmotica Pharmaceutical Business Overview
- Table 65. Osmotica Pharmaceutical GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 66. Osmotica Pharmaceutical GABA Receptor Agonist Drug Product Portfolio
- Table 67. Osmotica Pharmaceutical Recent Developments
- Table 68. NovaDel Pharma Company Information
- Table 69. NovaDel Pharma Business Overview
- Table 70. NovaDel Pharma GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 71. NovaDel Pharma GABA Receptor Agonist Drug Product Portfolio
- Table 72. NovaDel Pharma Recent Developments
- Table 73. H.LundBeck, Merck and Co Company Information
- Table 74. H.LundBeck, Merck and Co Business Overview
- Table 75. H.LundBeck, Merck and Co GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 76. H.LundBeck, Merck and Co GABA Receptor Agonist Drug Product Portfolio
- Table 77. H.LundBeck, Merck and Co Recent Developments
- Table 78. Elan Corporation Company Information
- Table 79. Elan Corporation Business Overview
- Table 80. Elan Corporation GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 81. Elan Corporation GABA Receptor Agonist Drug Product Portfolio
- Table 82. Elan Corporation Recent Developments
- Table 83. Biocodex Company Information
- Table 84. Biocodex Business Overview
- Table 85. Biocodex GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 86. Biocodex GABA Receptor Agonist Drug Product Portfolio
- Table 87. Biocodex Recent Developments
- Table 88. Athena Drug Delivery Solutions Company Information
- Table 89. Athena Drug Delivery Solutions Business Overview
- Table 90. Athena Drug Delivery Solutions GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 91. Athena Drug Delivery Solutions GABA Receptor Agonist Drug Product Portfolio
- Table 92. Athena Drug Delivery Solutions Recent Developments
- Table 93. Advicenne Company Information
- Table 94. Advicenne Business Overview
- Table 95. Advicenne GABA Receptor Agonist Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 96. Advicenne GABA Receptor Agonist Drug Product Portfolio
- Table 97. Advicenne Recent Developments
- Table 98. Global GABA Receptor Agonist Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 99. Global GABA Receptor Agonist Drug Sales by Region (2020-2025) & (k units)
- Table 100. Global GABA Receptor Agonist Drug Sales Market Share by Region (2020-2025)
- Table 101. Global GABA Receptor Agonist Drug Sales by Region (2026-2031) & (k units)
- Table 102. Global GABA Receptor Agonist Drug Sales Market Share by Region (2026-2031)
- Table 103. Global GABA Receptor Agonist Drug Revenue by Region (2020-2025) & (US$ Million)
- Table 104. Global GABA Receptor Agonist Drug Revenue Market Share by Region (2020-2025)
- Table 105. Global GABA Receptor Agonist Drug Revenue by Region (2026-2031) & (US$ Million)
- Table 106. Global GABA Receptor Agonist Drug Revenue Market Share by Region (2026-2031)
- Table 107. North America GABA Receptor Agonist Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 108. North America GABA Receptor Agonist Drug Sales by Country (2020-2025) & (k units)
- Table 109. North America GABA Receptor Agonist Drug Sales by Country (2026-2031) & (k units)
- Table 110. North America GABA Receptor Agonist Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 111. North America GABA Receptor Agonist Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 112. Europe GABA Receptor Agonist Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 113. Europe GABA Receptor Agonist Drug Sales by Country (2020-2025) & (k units)
- Table 114. Europe GABA Receptor Agonist Drug Sales by Country (2026-2031) & (k units)
- Table 115. Europe GABA Receptor Agonist Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 116. Europe GABA Receptor Agonist Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 117. Asia Pacific GABA Receptor Agonist Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 118. Asia Pacific GABA Receptor Agonist Drug Sales by Country (2020-2025) & (k units)
- Table 119. Asia Pacific GABA Receptor Agonist Drug Sales by Country (2026-2031) & (k units)
- Table 120. Asia Pacific GABA Receptor Agonist Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 121. Asia Pacific GABA Receptor Agonist Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 122. South America GABA Receptor Agonist Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 123. South America GABA Receptor Agonist Drug Sales by Country (2020-2025) & (k units)
- Table 124. South America GABA Receptor Agonist Drug Sales by Country (2026-2031) & (k units)
- Table 125. South America GABA Receptor Agonist Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 126. South America GABA Receptor Agonist Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 127. Middle East and Africa GABA Receptor Agonist Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 128. Middle East and Africa GABA Receptor Agonist Drug Sales by Country (2020-2025) & (k units)
- Table 129. Middle East and Africa GABA Receptor Agonist Drug Sales by Country (2026-2031) & (k units)
- Table 130. Middle East and Africa GABA Receptor Agonist Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 131. Middle East and Africa GABA Receptor Agonist Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 132. Global GABA Receptor Agonist Drug Sales by Type (2020-2025) & (k units)
- Table 133. Global GABA Receptor Agonist Drug Sales by Type (2026-2031) & (k units)
- Table 134. Global GABA Receptor Agonist Drug Sales Market Share by Type (2020-2025)
- Table 135. Global GABA Receptor Agonist Drug Sales Market Share by Type (2026-2031)
- Table 136. Global GABA Receptor Agonist Drug Revenue by Type (2020-2025) & (US$ Million)
- Table 137. Global GABA Receptor Agonist Drug Revenue by Type (2026-2031) & (US$ Million)
- Table 138. Global GABA Receptor Agonist Drug Revenue Market Share by Type (2020-2025)
- Table 139. Global GABA Receptor Agonist Drug Revenue Market Share by Type (2026-2031)
- Table 140. Global GABA Receptor Agonist Drug Price by Type (2020-2025) & (US$/unit)
- Table 141. Global GABA Receptor Agonist Drug Price by Type (2026-2031) & (US$/unit)
- Table 142. Global GABA Receptor Agonist Drug Sales by Application (2020-2025) & (k units)
- Table 143. Global GABA Receptor Agonist Drug Sales by Application (2026-2031) & (k units)
- Table 144. Global GABA Receptor Agonist Drug Sales Market Share by Application (2020-2025)
- Table 145. Global GABA Receptor Agonist Drug Sales Market Share by Application (2026-2031)
- Table 146. Global GABA Receptor Agonist Drug Revenue by Application (2020-2025) & (US$ Million)
- Table 147. Global GABA Receptor Agonist Drug Revenue by Application (2026-2031) & (US$ Million)
- Table 148. Global GABA Receptor Agonist Drug Revenue Market Share by Application (2020-2025)
- Table 149. Global GABA Receptor Agonist Drug Revenue Market Share by Application (2026-2031)
- Table 150. Global GABA Receptor Agonist Drug Price by Application (2020-2025) & (US$/unit)
- Table 151. Global GABA Receptor Agonist Drug Price by Application (2026-2031) & (US$/unit)
- Table 152. Key Raw Materials
- Table 153. Raw Materials Key Suppliers
- Table 154. GABA Receptor Agonist Drug Distributors List
- Table 155. GABA Receptor Agonist Drug Customers List
- Table 156. GABA Receptor Agonist Drug Industry Trends
- Table 157. GABA Receptor Agonist Drug Industry Drivers
- Table 158. GABA Receptor Agonist Drug Industry Restraints
- Table 159. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. GABA Receptor Agonist Drug Product Image
- Figure 5. Global GABA Receptor Agonist Drug Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global GABA Receptor Agonist Drug Market Size (2020-2031) & (US$ Million)
- Figure 7. Global GABA Receptor Agonist Drug Sales (2020-2031) & (k units)
- Figure 8. Global GABA Receptor Agonist Drug Average Price (US$/unit) & (2020-2031)
- Figure 9. Baclofen Product Image
- Figure 10. Bamaluzole Product Image
- Figure 11. Phenibut Product Image
- Figure 12. Gaboxadol Product Image
- Figure 13. Klonopin (clonazepam) Product Image
- Figure 14. Tiagbine Product Image
- Figure 15. Alzheimer Product Image
- Figure 16. Epilepsy and Seizure Product Image
- Figure 17. Obesity and Alcoholism Product Image
- Figure 18. Anxiety and Sleep Disorders Product Image
- Figure 19. Psychiatric Disorders and Depression Product Image
- Figure 20. Attention Deficit Hyperactivity Disorder (ADHD) Product Image
- Figure 21. Global GABA Receptor Agonist Drug Revenue Share by Manufacturers in 2024
- Figure 22. Global Manufacturers of GABA Receptor Agonist Drug, Manufacturing Sites & Headquarters
- Figure 23. Global Top 5 and 10 GABA Receptor Agonist Drug Players Market Share by Revenue in 2024
- Figure 24. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 25. Global GABA Receptor Agonist Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 26. Global GABA Receptor Agonist Drug Sales by Region in 2024
- Figure 27. Global GABA Receptor Agonist Drug Revenue by Region in 2024
- Figure 28. North America GABA Receptor Agonist Drug Market Size by Country in 2024
- Figure 29. North America GABA Receptor Agonist Drug Sales Market Share by Country (2020-2031)
- Figure 30. North America GABA Receptor Agonist Drug Revenue Market Share by Country (2020-2031)
- Figure 31. United States GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 32. Canada GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. Europe GABA Receptor Agonist Drug Market Size by Country in 2024
- Figure 34. Europe GABA Receptor Agonist Drug Sales Market Share by Country (2020-2031)
- Figure 35. Europe GABA Receptor Agonist Drug Revenue Market Share by Country (2020-2031)
- Figure 36. Germany GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. France GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. U.K. GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. Italy GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 40. Netherlands GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 41. Asia Pacific GABA Receptor Agonist Drug Market Size by Country in 2024
- Figure 42. Asia Pacific GABA Receptor Agonist Drug Sales Market Share by Country (2020-2031)
- Figure 43. Asia Pacific GABA Receptor Agonist Drug Revenue Market Share by Country (2020-2031)
- Figure 44. China GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. Japan GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. South Korea GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. India GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. Australia GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. China Taiwan GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. Southeast Asia GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 51. Southeast Asia GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 52. South America GABA Receptor Agonist Drug Market Size by Country in 2024
- Figure 53. South America GABA Receptor Agonist Drug Sales Market Share by Country (2020-2031)
- Figure 54. South America GABA Receptor Agonist Drug Revenue Market Share by Country (2020-2031)
- Figure 55. Mexico GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 56. Brazil GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 57. Argentina GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 58. Colombia GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 59. Middle East and Africa GABA Receptor Agonist Drug Market Size by Country in 2024
- Figure 60. Middle East and Africa GABA Receptor Agonist Drug Sales Market Share by Country (2020-2031)
- Figure 61. Middle East and Africa GABA Receptor Agonist Drug Revenue Market Share by Country (2020-2031)
- Figure 62. Turkey GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 63. Saudi Arabia GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 64. UAE GABA Receptor Agonist Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 65. Global GABA Receptor Agonist Drug Sales Market Share by Type (2020-2031)
- Figure 66. Global GABA Receptor Agonist Drug Revenue Market Share by Type (2020-2031)
- Figure 67. Global GABA Receptor Agonist Drug Price (US$/unit) by Type (2020-2031)
- Figure 68. Global GABA Receptor Agonist Drug Sales Market Share by Application (2020-2031)
- Figure 69. Global GABA Receptor Agonist Drug Revenue Market Share by Application (2020-2031)
- Figure 70. Global GABA Receptor Agonist Drug Price (US$/unit) by Application (2020-2031)
- Figure 71. GABA Receptor Agonist Drug Value Chain
- Figure 72. G
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
